Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Antisense Therapeutics Limited (ATHJF)
OTHER OTC:ATHJF
RESEARCH TOOLSreports
Holding ATHJF?
Track your performance easily
ATHJF Stock Chart & Stats
Day’s Range$0.05 - $0.05
52-Week Range― - ―
Previous Close$0.05
Volume2.73K
Average Volume (3M)N/A
Market Cap
$53.80M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Feb 26, 2025EPS Estimate
-$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume273
30 Day Avg. Volume667
Standard Deviation0.56
R-Squared0.02
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)112.18
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.17Price Target Upside240.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Antisense Therapeutics Limited News
PremiumCompany Announcements
Antisense Therapeutics Schedules Hybrid Annual General Meeting
PremiumCompany Announcements
Antisense Therapeutics Limited to Hold Annual General Meeting
PremiumCompany Announcements
Percheron Therapeutics Plans Major Securities Issuance
PremiumCompany Announcements
Percheron Therapeutics Unveils Significant Security Issuance
PremiumCompany Announcements
Percheron Therapeutics Requests Trading Halt for Capital Raising
PremiumCompany Announcements
Percheron Therapeutics Advances with Avicursen Study
PremiumCompany Announcements
Percheron Therapeutics Unveils Corporate UpdatePremiumCompany Announcements
Percheron’s Avicursen Shows Hope for EpilepsyOptions Prices
Currently, No data available
---
Ownership Overview
0.11%
Insiders
― Other Institutional Investors
99.89% Public Companies and
Individual Investors
ATHJF FAQ
What was Antisense Therapeutics Limited’s price range in the past 12 months?
Currently, no data Available
What is Antisense Therapeutics Limited’s market cap?
Currently, no data Available
When is Antisense Therapeutics Limited’s upcoming earnings report date?
Antisense Therapeutics Limited’s upcoming earnings report date is Feb 26, 2025 which is in 97 days.
How were Antisense Therapeutics Limited’s earnings last quarter?
Antisense Therapeutics Limited released its earnings results on Aug 29, 2024. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of -$0.004 by -$0.001.
Is Antisense Therapeutics Limited overvalued?
According to Wall Street analysts Antisense Therapeutics Limited’s price is currently Undervalued.
Does Antisense Therapeutics Limited pay dividends?
Antisense Therapeutics Limited does not currently pay dividends.
What is Antisense Therapeutics Limited’s EPS estimate?
Antisense Therapeutics Limited’s EPS estimate is -$0.02.
How many shares outstanding does Antisense Therapeutics Limited have?
Currently, no data Available
What happened to Antisense Therapeutics Limited’s price movement after its last earnings report?
Antisense Therapeutics Limited reported an EPS of -$0.005 in its last earnings report, missing expectations of -$0.004. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Antisense Therapeutics Limited?
Currently, no hedge funds are holding shares in ATHJF
---
Antisense Therapeutics Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.17 (240.00% Upside)
$0.17 (240.00% Upside)
Blogger Sentiment
Bullish
ATHJF Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.00%
12-Months-Change
Fundamentals
Return on Equity
-121.27%
Trailing 12-Months
Asset Growth
13.51%
Trailing 12-Months
Company Description
Antisense Therapeutics Limited
Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded in November 13, 2000 and is headquartered in Toorak, Australia.
---
ATHJF Stock 12 Month Forecast
Average Price Target
$0.17
▲(240.00% Upside)
Technical Analysis
Best Analysts Covering ATHJF
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-42.15%
reiterated a buy rating 3 months ago
Copying Iain Wilkie's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -42.15% per trade.
---